Binz Biotech Consulting

Kaspar is further co-founder and member of the board of directors of arcoris bio AG, a company providing next-generation multiplex biomolecule detection technology. He further serves at the board of directors of Althea Genomics SA, a company enabling high-throughput RNAseq. He is co-founder of Molecular Partners (SIX/NASDAQ: MOLN), a Swiss clinical stage biotech company developing DARPin® drugs for therapeutic applications. With his entrepreneurial approach Kaspar was key in the establishment of Molecular Partners as a successful biotech company, and in the establishment of Molecular Partners’ pipeline.

With more than 20 years of experience in building biotech and life sciences companies, Kaspar enjoys passing on his hands-on experience.

Kaspar is extremely grateful to have had the opportunity to work with some of the most brilliant applied biotech-minds of our times. He was educated at the Royal Institute of Technology in Stockholm, Sweden, in the group of Prof. Mathias Uhlén, and holds a M.Sc. in biotechnology from the European school of biotechnology in Strasbourg, France. He invented and developed the designed ankyrin repeat protein technology (DARPin® technology, the basis of Molecular Partners) during his PhD studies with Prof. Andreas Plückthun at the University of Zürich, Switzerland. His thesis was awarded with the annual prize of the University of Zürich. Molecular Partners and the designed ankyrin repeat protein technology have further been awarded with several prizes including the Swiss Technology Award 2005, the Swiss Venture 2004 business plan competition award, and the De Vigier Foundation award 2005. Kaspar has published widely in the areas of protein engineering and drug development and is inventor on numerous patents and patent applications.